LOS ANGELES, CA--(Marketwire - November 4, 2009) - MMR Information Systems, Inc. (OTCBB: MMRF) www.mymedicalrecords.com, announced today it has retained Global Research Services LLC, www.grs-cro.com, a full-service clinical trials management organization, to assist the Company in its efforts to accelerate bringing to market its patented anti-CD20 monoclonal antibodies. Anti-CD20 antibodies are useful in treating B-Cell malignancies, including Non-Hodgkin Lymphoma (NHL) and additional B-Cell mediated conditions such as rheumatoid arthritis. Global Research Services specializes in serving sponsors of Phase I-IV research. MMRF's anti-CD20 antibody asset is potentially a candidate for the next generation Rituximab, marketed under the trade name Rituxan® in the United States by Biogen Idec and Genentech (wholly owned member of the Roche Group) and under the name MabThera® by Roche in the rest of the world except Japan, where it is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. Rituxan is one of the world's most successful monoclonal antibodies with reported total sales in 2008 in excess of US $5.4 billion.

MMR Information Systems recently filed for extension of the Company's Patent Cooperation Treaty (PCT) patent application on anti-CD20 monoclonal antibodies to the national phase through filings in major European, Asian, North American, and South American markets.

Global Research Services operates from offices and/or presence on the ground across six continents of the world, with experience in over 135 protocols with 35 Sponsors in 3400 investigational sites, encompassing all aspects of clinical trials management. The Global team has extensive experience in designing, developing and implementing clinical development programs that accelerate time-to-market for a wide range of new drugs, biologics and medical devices. Global Research Services provides full services from Phase I through final regulatory approval and ultimate commercialization.

Robert H. Lorsch, Chairman and CEO of MMR Information Systems, Inc., noted, "In the Personal Health Records business, the buzzword is 'meaningful use.' With regard to the fighting of cancer, the buzzword could be a 'meaningful difference.' Our health information products have meaning for meaningful use, and we look forward to the possibility that our anti-CD20 antibodies can make a meaningful difference."

About MMR Information Systems, Inc.

MMR Information Systems, Inc. (OTCBB: MMRF), through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, unions and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for small to mid-size physician practices. MMR clients include AFL-CIO, Alexian Brothers Hospital Network, Coverdell, LegalZoom, The Latino Coalition, MedicAlert, NRA, Qvisory, XN Financial and others. MMR is also an integrated service provider on Google Health. To learn more about MMR Information Systems, Inc. visit www.mmrinformationsystems.com.

About GRSworldwide

Global Research Services (GRS) is an international clinical research organization supplying a full range of clinical trial services to pharmaceutical, biotech, and medical device companies. Headquartered in Maryland, GRS operates offices in North America, South America, Europe and Asia and helps clients worldwide complete their clinical development programs through a global site network, experienced staff, effective management plans and premier capabilities. www.grs-cro.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements regarding the Company's anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the development and approval of biotechnology and biopharmaceutical product candidates and additional risks discussed in the Company's filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company's behalf) are qualified by the cautionary statements in this notice. MMR Information Systems, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact Information: CONTACT: Bobbie Volman MMR Information Systems, Inc. (310) 476-7002, Ext. 2005 bvolman@mmrmail.com Michael Selsman Public Communications Co. (310) 553-5732 ms@publiccommunications.biz